## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. 3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years**
- Source: Finviz | 20251129T153000 | Bullish | Relevance: 99%
- This article identifies three high-yielding dividend growth stocks—AbbVie (ABBV), Home Depot (HD), and ExxonMobil (XOM)—that can generate passive income and diversify a portfolio. These companies operate in different sectors and have long histories of consistently increasing their dividend payouts. The piece details each company's dividend history, current yield, and financial performance, highlighting them as ideal long-term investments.

**2. AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets**
- Source: ts2.tech | 20251130T225044 | Somewhat-Bullish | Relevance: 99%
- AbbVie (ABBV) heads into December 1, 2025, with its stock trading near $227, reflecting a strong year but a recent dip due to Medicare pricing news. Key developments include a significant reimbursement win in Canada for Skyrizi, U.S. Medicare price cuts affecting Linzess and Vraylar, and ongoing analyst evaluation. The company's Q3 2025 results showed robust immunology growth, raised EPS guidance, and a dividend increase, despite some portfolio softness and policy risks.

**3. AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts**
- Source: ts2.tech | 20251201T221915 | Bullish | Relevance: 99%
- This article analyzes AbbVie's stock performance as of December 2025, highlighting key drivers such as the atogepant migraine data, strong Q3 2025 earnings which beat expectations, and the company's updated 2026 outlook. It discusses how the immunology franchise, led by Skyrizi and Rinvoq, is offsetting the Humira patent cliff, while new oncology assets and U.S. manufacturing investments position AbbVie favorably, despite manageable impacts from Medicare price cuts. Analyst sentiment remains positive, seeing AbbVie as a "quality compounder" with stable growth and a reliable dividend.

**4. AbbVie Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T163100 | Neutral | Relevance: 99%
-  AbbVie Inc. (ABBV) stock fell by 1.14% to $225.11 on Monday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also experienced declines. The company's stock closed 8.05% below its 52-week high, which was reached on October 1st.

**5. AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength**
- Source: ts2.tech | 20251130T103626 | Somewhat-Bullish | Relevance: 98%
- AbbVie Inc. (ABBV) faces a mixed but generally constructive outlook as of November 30, 2025, with its stock up over 30% year-to-date despite a recent analyst downgrade from "Strong Buy" to "Buy" by Wall Street Zen. The company boasts significant FDA approvals for EPKINLY and progress with Skyrizi's reimbursement, along with a 5.5% dividend increase, highlighting strong fundamentals and pipeline momentum. While Medicare pricing pressures and accounting-driven earnings optics present caution flags, the overall sentiment remains bullish due to robust cash flow and strategic growth initiatives.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.8x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $398.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.8 |
| Current P/E | 21.2 |
| YoY Growth | 34.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from -1.6% to -4.6% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >3.0% for momentum thesis). Underperforming sector by 6.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.60% (CS: 5) | Weak |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | -0.46 | Bearish |
| vs SMA20 | 0.993x | Below |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $225.11
- **Stop Loss:** $213.89 (5.0% risk)
- **Target:** $236.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $14,857.26
- **Portfolio %:** 14.86%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*